Literature DB >> 2999797

Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations.

S Pahwa, R Pahwa, C Saxinger, R C Gallo, R A Good.   

Abstract

The etiologic agent for the acquired immunodeficiency syndrome (AIDS) is now firmly established as the retrovirus termed the human T-lymphotropic virus type III (HTLV-III) or the lymphadenopathy-associated virus, LAV. The disease is characterized by profound and progressive loss of immunity, but molecular evidence indicates that only a few cells in peripheral blood are being productively infected with this virus. In the present study we have investigated a disrupted HTLV-III viral preparation for biologic effects on normal lymphoid cells. Relatively dilute concentrations of this preparation were found to stimulate immunoglobulin secretion by peripheral blood lymphocytes; at the same dosages, the preparation was inhibitory for the B-cell differentiation responses that are induced with other known polyclonal B-cell activators, pokeweed mitogen, Staphylococcus aureus, and Epstein-Barr virus. This preparation was also inhibitory at high concentrations for T-lymphocyte proliferative responses to phytomitogens and antigens and resulted in a reduced expression of Tac antigen on phytohemagglutinin-activated lymphocytes. Paradoxically, incubation of lymphocytes of certain healthy donors with the HTLV-III preparation alone resulted in increased expression of Tac and Leu-12 antigens. These findings show that a disrupted preparation of HTLV-III virus can mimic many of the immunologic abnormalities present in patients with HTLV-III infection. Nonviable viral proteins may be responsible for some of the immunologic perturbations that occur in HTLV-III-infected states.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999797      PMCID: PMC391470          DOI: 10.1073/pnas.82.23.8198

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

Review 1.  Immunodepression by oncogenic viruses.

Authors:  P B Dent
Journal:  Prog Med Virol       Date:  1972

2.  Polyclonal and antigen-specific B-cell responses in patients with common variable immunodeficiency.

Authors:  S G Pahwa; M K Hoffman; R N Pahwa; R A Good
Journal:  J Clin Immunol       Date:  1982-07       Impact factor: 8.317

Review 3.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

4.  Retrovirus-mediated immunosuppression. I. FeLV-UV and specific FeLV proteins alter T lymphocyte behavior by inducing hyporesponsiveness to lymphokines.

Authors:  C G Orosz; N E Zinn; R G Olsen; L E Mathes
Journal:  J Immunol       Date:  1985-05       Impact factor: 5.422

5.  Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.

Authors:  L Montagnier; J Gruest; S Chamaret; C Dauguet; C Axler; D Guétard; M T Nugeyre; F Barré-Sinoussi; J C Chermann; J B Brunet
Journal:  Science       Date:  1984-07-06       Impact factor: 47.728

6.  B-cell immunodeficiency in acquired immune deficiency syndrome.

Authors:  A J Ammann; G Schiffman; D Abrams; P Volberding; J Ziegler; M Conant
Journal:  JAMA       Date:  1984-03-16       Impact factor: 56.272

7.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  50 in total

1.  Identification of NAD+ synthetase from Streptococcus sobrinus as a B-cell-stimulatory protein.

Authors:  Isabel Veiga-Malta; Margarida Duarte; Márcia Dinis; Pedro Madureira; Paula Ferreira; Arnaldo Videira
Journal:  J Bacteriol       Date:  2004-01       Impact factor: 3.490

2.  A gp120 HIV peptide with high similarity to HLA class II beta chains enhances PPD-specific and autoreactive T cell activation.

Authors:  O Pugliese; M Viora; B Camponeschi; P Cordiali Fei; F Caprilli; A Chersi; M Evangelista; A M Di Massimo; V Colizzi
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

3.  Protective effect of a T-cell-dependent immunosuppressive, B-cell-mitogenic protein (F3'EP-Si, or P90) produced by Streptococcus intermedius.

Authors:  M Lima; A Bandeira; D Portnoi; A Ribeiro; M A Chaves
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

4.  Influence of inactivated feline retrovirus on feline alpha interferon and immunoglobulin production.

Authors:  M Yasuda; R A Good; N K Day
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

Review 5.  B cell responses to HIV and the development of human monoclonal antibodies.

Authors:  J E Boyd; K James
Journal:  Clin Exp Immunol       Date:  1992-05       Impact factor: 4.330

6.  Concomitant infection of HTLV-I and HIV-1: prevalence of IgG and IgM antibodies in Washington, D.C. area.

Authors:  K S Chang; L C Wang; C L Gao; S Alexander; R C Ting; A Bodner; T Log; A F Kuo; P Strickland
Journal:  Eur J Epidemiol       Date:  1988-12       Impact factor: 8.082

7.  Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes.

Authors:  S Pahwa; R Pahwa; R A Good; R C Gallo; C Saxinger
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

8.  B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters.

Authors:  H Mizuma; S Litwin; S Zolla-Pazner
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

9.  Human immunodeficiency virus proteins induce the inhibitory cAMP/protein kinase A pathway in normal lymphocytes.

Authors:  B Hofmann; P Nishanian; T Nguyen; P Insixiengmay; J L Fahey
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

10.  Impaired proliferative capacity and abnormal cytokine profile of naive and memory CD4 T cells from HIV-seropositive patients.

Authors:  A Cayota; F Vuillier; D Scott-Algara; V Feuillie; G Dighiero
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.